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Graft-versus-host disease (GVHD) remains a major chal-
lenge for progress in allogeneic hematopoietic cell trans-
plantation. Steroids continue to be the most effective ﬁrst-
line therapy and there is no standard accepted second-line
therapy for either acute or chronic GVHD. Moreover, there
are no Food and Drug Administration (FDA)eapproved
agents for GVHD indications. Extracorporeal photopheresis
(ECP) is a cell-based immunomodulatory therapy that in-
volves separation of leukocytes from whole blood by
apheresis, followed by ex vivo treatment of the cells with the
photosensitizer 8-methoxypsoralen, exposure to ultraviolet
A irradiation, and subsequent reinfusion to the patient [1].
ECP was ﬁrst described for clinical use in the treatment of
cutaneous T cell lymphoma in 1987 and was FDA approved
for this indication in 1998. Since that time, ECP has been
extensively used in the treatment of acute and chronic
GVHD, in many autoimmune diseases, and after solid organ
transplantation; however, ECP is not FDA approved for use in
these settings.
Though some of the mechanisms by which ECP exerts its
clinical effects have been described, much remains to be
elucidated regarding the complex interplay of the immune
processes. What we do know is that there are several layers
in the mechanism of ECP: (1) direct cytotoxicity of T effector
cells, although this impacts only 5% to 10% of lymphocytes;
hence, it is unlikely to be a major underlying mechanism;
(2) induction of self-tolerance after nonimmunogenic
apoptosis of the lymphocytes and subsequent uptake by
antigen-presenting cells in the presence of a noninﬂam-
matory cytokine milieu after ECP; and (3) direct impact on
dendritic cells with induction of a tolerogenic phenotype,
further leading to allo-speciﬁc tolerance, a decrease in
alloreactive T cell proliferation, and increase in production
of IL-10, which is a tolerogenic cytokine. In addition, several
studies have demonstrated an impact on lymphocyte pro-
ﬁles after ECP, with an increase in regulatory T cells and
other key mediators that control GVHD, and a shift away
from differentiation of GVHD effectors, such as Th1 and
Th17 cells [2,3].
In this issue, Calore et al. present their ﬁndings from a
retrospective analysis of their experience at a single insti-
tution using ECP in the treatment of steroid-refractory, ste-
roid-dependent, or steroid-intolerant acute GVHD (aGVHD)
in pediatric patients undergoing allogeneic hematopoietic
cell transplantation over a course of 16 years, which is the
largest pediatric aGVHD cohort published to date [4]. The
ﬁndings reported highlight several important points
regarding ECP in aGVHD: (1) vast anecdotal experience with
ECP has demonstrated efﬁcacy in pediatric patients in
aGVHD, but this has yet to be conﬁrmed in more rigorously
deﬁned trials; (2) the ability to come off steroids and
immunosuppressive therapy is a key advantage with ECP,
and the unique technical and logistic issues are minimized at
an experienced institution; and (3) now is the time for ran-
domized, prospective trials with standardized treatment,
response, and follow-up criteria to conﬁrm these experi-
ences, deﬁne the best role for ECP, better understand
mechanisms, and assess the feasibility of widespread use
of ECP.
The authors report an overall response rate of 83%,
including a complete response (CR) rate of 72% in their cohort.
Not surprisingly, transplantation-relatedmortality and overall
survival were signiﬁcantly better for those who had a
response versus those who did not (transplantation-related
mortality, 3% and 58%; overall survival, 78% and 30%, respec-
tively). There was not a signiﬁcant difference in the CR rate
among the 3 subgroups requiring second-line strategies, but
the groupsmay have been too small to detect a difference. The
response rates reported here compare favorably to previous
reports from other institutions, where CR rates in a pediatric
aGVHD population have ranged from 32% to 60% [5-10]. Of
note, all of these studies, including the current study, were
nonrandomized and not uniform in terms of study criteria,
thus limiting the ability to make comparisons and ultimate
conclusions. Will these response rates hold up in randomized,
prospective trials with well-deﬁned and standardized
eligibility, response assessment, and follow-up criteria? For
example, in a recent analysis of 82 studies evaluating 9
interventions in chronic GVHD, adherence to the National
Institutes of Health consensus clinical trials design guidelines
was associated with a signiﬁcant reduction in response rates,
suggesting the role of investigator bias [11].
In regards to safety, side effects were mild and compli-
cations were rare in this retrospective study. However, this
study was done in an institution with extensive experience
using ECP; thus, it is not known if results would differ if
evaluated elsewhere. Moreover, the technical and logistic
obstacles of ECP present the biggest disadvantages: volume
of blood required, venous access or need for central line
placement that can be complicated by infection or throm-
bosis, time and frequency of the procedures that may not be
feasible for patients and caregivers, access and travel to
centers with expertise in ECP, and the substantial costs
associated with long-term therapy, if needed. These are the
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“adverse effects” that will need to be carefully evaluated in
prospective studies in regards to weighing the risks and
beneﬁts of therapy.
The unique safety proﬁle of ECP does include the lack of
major immunosuppressive effects, whichmakes this strategy
particularly attractive compared with other GVHD therapies,
and there is no increased risk of infections or relapse of the
underlying disease. Of note, ECP has been evaluated some-
what more rigorously in the treatment of chronic GVHD,
including 1 randomized trial, where response rates of 31% to
93% have been reported, with particularly high responses in
cutaneous manifestations [12].
The ideal role of ECP in the treatment of GVHD still has yet
to be determined. Despite the paucity of randomized pro-
spective trials, ECP is a well-established, accepted treatment
for steroid-refractory or steroid-dependent aGVHD and
chronic GVHD, and the current study strengthens this body
of literature while highlighting important features for
further investigations. Whether ECP should be used in
conjunction with or in place of steroids in the ﬁrst-line
setting (as was utilized and shown to be effective in the
current study) or as a preventive therapy as part of a pro-
phylactic regimen remains to be determined. There are 10
ongoing trials on clinicaltrials.gov asking these and similar
questions. In addition, combining ECP with other immuno-
modulatory or targeted therapies is a potentially promising
pursuit, because of the ability to synergize the immune
effects and because ECP is unlikely to have signiﬁcant toxicity
interactions. Future study will also need to address the
unanswered questions regarding immunologic mechanisms.
For example, what are the contributions of NK cells, neu-
trophils, and B cells, and what is the exact role of cytokines in
the immunomodulatory effects? These ﬁndings may lead to
the development of biomarkers for predictors or monitoring
of response, another important area of study where trials are
ongoing. Ideally, identifying the key therapeutic mechanism
of ECP may lead to information for developing more targeted
and more practical ways to treat GVHD. In the meantime,
however, the key task is to execute well-designed, prospec-
tive, randomized trials to conclusively address the questions
of comparative effectiveness and its real magnitude. Almost
30 years after the development of this procedure, the role of
ECP in GVHD is evolving, and there will be much that is
elucidated in the coming years from both clinical and
immunologic studies.
ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to disclose.
Conﬂict of interest statement: There are no conﬂicts of
interest.
Disclaimer: The opinions expressed here are those of the
authors and do not represent the ofﬁcial position of the
National Cancer Institute, National Institutes of Health, or
the United States Government.
REFERENCES
1. Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of
extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;
28(Suppl 1):1-37.
2. Ratcliffe N, Dunbar NM, Adamski J, et al. National Institutes of Health
State of the Science Symposium in Therapeutic Apheresis: scientiﬁc
opportunities in extracorporeal photopheresis. Transfus Med Rev. 2015;
29:62-70.
3. Bruserud O, Tvedt TH, Paulsen PQ, et al. Extracorporeal photopheresis
(photochemotherapy) in the treatment of acute and chronic graft
versus host disease: immunological mechanisms and the results from
clinical studies. Cancer Immunol Immunother. 2014;63:757-777.
4. Calore E, Marson P, Pillon M, et al. Treatment of acute graft-versus-host
disease in childhood with extracorporeal photochemotherapy/photo-
pheresis: the Padova experience. Biol Blood Marrow Transplant. 2015;
21:1963-1972.
5. Berger M, Pessolano R, Albiani R, et al. Extracorporeal photopheresis for
steroid resistant graft versus host disease in pediatric patients: a pilot
single institution report. J Pediatr Hematol Oncol. 2007;29:678-687.
6. Gonzalez Vicent M, Ramirez M, Sevilla J, et al. Analysis of clinical
outcome and survival in pediatric patients undergoing extracorporeal
photopheresis for the treatment of steroid-refractory GVHD. J Pediatr
Hematol Oncol. 2010;32:589-593.
7. Kanold J, Merlin E, Halle P, et al. Photopheresis in pediatric graft-
versus-host disease after allogeneic marrow transplantation: clinical
practice guidelines based on ﬁeld experience and review of the liter-
ature. Transfusion. 2007;47:2276-2289.
8. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photo-
chemotherapy for paediatric patients with graft-versus-host disease
after haematopoietic stem cell transplantation. Br J Haematol. 2003;
122:118-127.
9. Perotti C, Del Fante C, Tinelli C, et al. Extracorporeal photo-
chemotherapy in graft-versus-host disease: a longitudinal study on
factors inﬂuencing the response and survival in pediatric patients.
Transfusion. 2010;50:1359-1369.
10. Salvaneschi L, Perotti C, Zecca M, et al. Extracorporeal photo-
chemotherapy for treatment of acute and chronic GVHD in childhood.
Transfusion. 2001;41:1299-1305.
11. Olivieri J, Manfredi L, Postacchini L, et al. Consensus recommendations
for improvement of unmet clinical needs - the example of chronic
graft-versus-host disease: a systematic review and meta-analysis.
Lancet Haematol. 2015;2:e297-e305.
12. Greinix HT, Worel N, Just U, Knobler R. Extracorporeal photopheresis in
acute and chronic graft-versus-host disease. Transfus Apher Sci. 2014;
50:349-357.
A. Im, S.Z. Pavletic / Biol Blood Marrow Transplant 21 (2015) 1859e18621862
